B 
Bristol-Myers Squibb BMY · USD
Health Care · Pharmaceuticals · US listing · 🇺🇸 United States
S&P 500
62.14
0.00%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
At a glance
Figures in USD, from our data supplier.
Revenue
$48.20bn
FY2016FY2025
Net income
$7.05bn
FY2016FY2025
Free cash flow
$12.85bn
FY2016FY2025
Shareholders' equity
$18.47bn
FY2016FY2025
Income statement
Fiscal years
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $48.20bn | $48.30bn | $45.01bn | $46.16bn | $46.38bn | $42.52bn | $26.14bn | $22.56bn | $20.78bn | $19.43bn |
| Research and development | $9.95bn | $9.78bn | $9.21bn | $9.41bn | $9.53bn | $9.56bn | $5.95bn | $5.13bn | $4.97bn | $4.41bn |
| Operating income | $11.22bn | $9.66bn | $8.47bn | $9.27bn | $9.54bn | $4.49bn | $6.44bn | $6.39bn | $5.24bn | $5.35bn |
| Net income | $7.05bn | −$8.95bn | $8.03bn | $6.33bn | $6.99bn | −$8.99bn | $3.44bn | $4.92bn | $1.01bn | $4.46bn |
| Diluted earnings per share | 3.46 | -4.39 | 3.95 | 2.98 | 3.15 | -3.99 | 1.79 | 3.01 | 0.61 | 2.65 |
Balance sheet
At each fiscal year end
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $90.04bn | $92.60bn | $95.16bn | $96.82bn | $109.31bn | $118.48bn | $129.94bn | $34.99bn | $33.55bn | $33.71bn |
| Cash and short-term investments | $10.67bn | $10.86bn | $12.28bn | $9.25bn | $17.22bn | $16.45bn | $15.39bn | $8.76bn | $6.81bn | $6.35bn |
| Total liabilities | $71.53bn | $76.22bn | $65.67bn | $65.70bn | $73.31bn | $80.60bn | $78.25bn | $20.86bn | $21.70bn | $17.36bn |
| Debt | $45.11bn | $49.65bn | $39.77bn | $39.32bn | $44.55bn | $50.68bn | $46.73bn | $7.35bn | $7.96bn | $6.71bn |
| Shareholders' equity | $18.47bn | $16.34bn | $29.43bn | $31.06bn | $35.95bn | $37.82bn | $51.60bn | $14.03bn | $11.74bn | $16.18bn |
| Shares outstanding | 2,041m | 2,037m | 2,033m | 2,124m | 2,219m | 2,252m | 1,918m | 1,637m | 1,643m | 1,680m |
Cash flow
Fiscal years
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | $14.16bn | $15.19bn | $13.86bn | $13.07bn | $16.21bn | $14.05bn | $8.07bn | $7.07bn | $5.28bn | $3.06bn |
| Capital spending | −$1.31bn | −$1.25bn | −$1.21bn | −$1.12bn | −$973.0m | −$753.0m | −$836.0m | −$951.0m | −$1.05bn | −$1.22bn |
| Free cash flow | $12.85bn | $13.94bn | $12.65bn | $11.95bn | $15.23bn | $13.30bn | $7.23bn | $6.12bn | $4.22bn | $1.84bn |
| Dividends paid | −$5.04bn | −$4.86bn | −$4.74bn | −$4.63bn | −$4.40bn | −$4.08bn | −$2.68bn | −$2.61bn | −$2.58bn | −$2.55bn |
Latest quarters
By quarter end
| Jun 2026 | Mar 2026 | Dec 2025 | Sept 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sept 2024 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $12.97bn | $11.49bn | $12.50bn | $12.22bn | $12.27bn | $11.20bn | $12.34bn | $11.89bn |
| Operating income | $4.03bn | $3.37bn | $2.81bn | $3.64bn | $3.77bn | $3.50bn | $2.53bn | $2.29bn |
| Net income | $3.32bn | $2.68bn | $1.09bn | $2.20bn | $1.31bn | $2.46bn | $72.0m | $1.21bn |
| Diluted earnings per share | 1.62 | 1.31 | 0.53 | 1.08 | 0.64 | 1.20 | 0.04 | 0.59 |
| Cash from operations | $3.39bn | $1.10bn | $1.97bn | $6.31bn | $3.92bn | $1.95bn | $4.44bn | $5.59bn |
| Capital spending | −$305.0m | −$347.0m | −$370.0m | −$320.0m | −$361.0m | −$260.0m | −$378.0m | −$324.0m |
| Free cash flow | $3.09bn | $757.0m | $1.60bn | $5.99bn | $3.56bn | $1.69bn | $4.06bn | $5.27bn |
| Total assets | $87.63bn | $86.48bn | $90.04bn | $96.89bn | $94.68bn | $92.43bn | $92.60bn | $93.67bn |
| Cash and short-term investments | $11.07bn | $10.49bn | $10.67bn | $16.50bn | $13.60bn | $11.78bn | $10.86bn | $8.09bn |
| Debt | $43.12bn | $44.66bn | $45.31bn | $49.19bn | $49.38bn | $49.88bn | $49.83bn | $49.92bn |
| Shareholders' equity | $22.32bn | $20.07bn | $18.47bn | $18.55bn | $17.43bn | $17.39bn | $16.34bn | $17.14bn |
Financial ratios
Data as of 8 Sept 2026
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | |
|---|---|---|---|---|---|---|
| Operating margin | 23.3% | 20.0% | 18.8% | 20.1% | 20.6% | 10.6% |
| Net margin | 14.6% | -18.5% | 17.8% | 13.7% | 15.1% | -21.2% |
| Return on equity | 38.2% | -54.8% | 27.3% | 20.4% | 19.5% | -23.8% |
| Return on assets | 7.8% | -9.7% | 8.4% | 6.5% | 6.4% | -7.6% |
| Free cash flow yield | 11.3% | 12.1% | 11.1% | 10.0% | 11.6% | 9.8% |
| Revenue growth | -0.2% | 7.3% | -2.5% | -0.5% | 9.1% | 62.6% |
| Earnings growth | -178.8% | -211.5% | 26.8% | -9.5% | -177.8% | -361.6% |
| Current ratio | 1.26x | 1.25x | 1.43x | 1.25x | 1.52x | 1.58x |
| Debt to equity | 2.45x | 3.05x | 1.36x | 1.27x | 1.24x | 1.34x |
| Equity ratio | 20.5% | 17.6% | 30.9% | 32.1% | 32.9% | 31.9% |
| Interest coverage | 5.93x | 4.96x | 7.27x | 7.53x | 7.15x | 3.16x |
| R&D as a share of sales | 20.6% | 20.3% | 20.5% | 20.4% | 20.6% | 22.5% |
| Buybacks as a share of market value | -0.2% | -0.2% | 4.3% | 4.3% | 1.5% | -17.4% |
Growth per year
Compound annual rate
| 3 years | 5 years | 10 years | |
|---|---|---|---|
| Revenue | 1.4% | 2.5% | 11.3% |
| Operating income | 6.6% | 20.1% | 11.0% |
| Net income | 3.7% | — | 16.2% |
Average margins
Over each period
| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Operating margin | 21.6% | 20.6% | 19.0% | 20.9% |
| Net margin | -2.0% | 6.6% | 3.8% | 6.8% |
Valuation history
At each fiscal year end
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Price to earnings | 15.6 | -12.9 | 13.0 | 24.1 | 19.8 | -15.5 | 35.8 | 17.3 | 100.0 | 22.0 |
| Price to sales | 2.3 | 2.4 | 2.3 | 3.3 | 3.0 | 3.3 | 4.7 | 3.8 | 4.8 | 5.0 |
Market value over time
31 Oct 2016 to 4 Sept 2026, in USD
$85.48bn$136.85bn
Share price return
Finished calendar years
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Return | -6% | 9% | -29% | 19% | -0% | -2% | 27% | -18% | 4% | -12% |
Dividends and splits
Per share, in the currency the company pays
Paid for 37 years. Last went ex-dividend on 2 Oct 2026.
| FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | |
|---|---|---|---|---|---|---|---|---|
| Paid in the year | 1.89 | 2.49 | 2.42 | 2.31 | 2.19 | 2.01 | 1.84 | 1.68 |
- 2-for-1 split · 1 Mar 1999
- 2-for-1 split · 3 Mar 1997
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.